At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 17 target
Drug / intervention
Topical oxybutynin spray +2 moredrug
Likely dose
Not stated in record
Key inclusion· 2
- ✓Age 18 to 45 years
- ✓No prior drug or treatment for hyperhidrosis within 30 days
Key exclusion· 5
- ✕Hypersensitivity to oxybutynin hydrochloride
- ✕Menopausal symptoms
- ✕Skin lesions in the armpit
- ✕Pregnancy or inadequate contraception
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05102396Phase 2RecruitingUpdate OverdueUpdated 25mo ago · Completion was 24mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Topical Oxybutynin Deodorant for Axillary Hyperhidrosis: Local or Systemic Effect? The TODAY Trial
In Brief
A Phase 2 clinical trial evaluating Topical oxybutynin spray, Topical placebo spray, and 1 other intervention for Hyperhidrosis and 6 related conditions. Currently recruiting, targeting 17 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
The TODAY trial is a study to evaluate the efficacy and safety of topical oxybutynin deodorant for use in patients with axillary hyperhidrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperhidrosis, Oxybutynin, Sweat Gland Diseases, Skin Diseases, Autonomic Agents, Cholinergic Antagonists, Parasympatholytics
CountriesBrazil
CollaboratorsScience Valley Research Institute
Timeline
Phase 2RecruitingOverdue
20222023202420252026
First PostedNov 2021
Enrollment StartSep 2022
Primary CompletionJun 2024
Study CompletionAug 2024
TodayJul 2026
First PostedNov 1, 2021
Enrollment StartSep 26, 2022
Primary CompletionJun 30, 2024
Study CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.7 years ago
Interventions
Topical oxybutynin spraydrug
Participants will receive topical oxybutynin spray (10%).
Topical placebo spraydrug
Participants will receive topical placebo spray.
Oral oxybutynindrug
Participants will receive oxybutynin (tablets).